The latest news and information from Oncotarget

Researchers and scientists studying treatments for Triple Negative Breast Cancer have discovered that the hormone-resistant cancer cells are more likely to accept treatment if they release a certain protein named Estrogen Receptor Beta. Specifically, the proteins which tells the cancer cells where to spread and divide, cyclin-dependent kinases, were affected. The Estrogen Receptor Beta can be found in patients without Estrogen Receptor Alpha, allowing researchers to narrow the target receptor down and further explore the effects. Because this form of cancer is particularly aggressive and spreads rapidly, researchers were very excited to discover this information. Follow Oncotarget on Twitter.

This discovery was tested in the lab on a mouse with the TNB breast cancer cells attached to it. The estrogen used helped slow or even prevent further growth, as well as potentially cause the tumor to regress. The head of the research department, Dr. Hawse, is looking forward to further evaluations in the lab as well as in animals. If they are able to move on to clinical trials, they believe this discovery might lead to improved effectiveness when treating Triple Negative Breast Cancer.


The oncology publication Oncotarget provided four researchers with sponsorships to the Frontiers in Cancer Science 2017 conference. The conference was held in Singapore on November 6-8 and featured some of the world’s top scientists involved in studying potential treatments for cancer. The editor-in-chief of Oncotarget, Mikhail Blagosklonny, sponsored the researchers in order to present research on important topics in the field of oncology.

The researchers included Mohd Anas Shamsi from India, Rajni Kumari from India, Ruhi Sandeep Deshmukh from India, and Vladan Milosevic from Italy. Dr. Shamsi presented the latest information on treatments for renal cancer, while Dr. Kumari presented information on mutations of the enzyme Caspase-10. Dr. Deshmukh presented information on the regulator Cyclin F, and Dr. Milosevic discussed the resistance of tumors related to exposure to asbestos.

There were seven research institutes hosting the conference. Research institutes from Singapore included the Cancer Science Institute, the Institute of Molecular and Cell Biology, and the Genome Institute. Other institutions included Duke-NUS Medical School from the United States and Singapore, as well as the Lee Kong Chian School of Medicine. Learn more at

Genomic Research: Omar Boraie Makes a Remarkable Gift to the Cancer Fight

On October 21, 2015, NJ Biz released a story spotlighting cancer research at Rutgers Cancer Institute of New Jersey. The reporting focused on the establishment of the Omar Boraie Chair in Genomic Science. For those who are unfamiliar with endowed chairs, they are widely considered the top standard of continued support for a university that commits to an academic discipline.

In this case, that discipline is cancer research, and the support comes in the form of a $1.5 million pledge from the new Omar Boraie Chair. The article goes on to explain that the chair is named after a New Brunswick developer, Omar Boraie, and is part of a campaign by Rutgers known as the “18 Chair Challenge”. The concept is that an anonymous donor will match the $1.5 million donations resulting in a $3 million endowment for each.

For many years, researchers have battled the scourge of cancer seeking to find more effective treatments and hoping to discover what has long been an elusive cure. According to, the research conducted at Rutgers focuses on the relatively new discoveries in the field of Genomics. The study of genes is rapidly changing the approach to cancer diagnosis and treatment.

Understanding cancer on a genetic level allows oncologists to create precise therapies unique to each patient. Breakthroughs in this kind of precision medicine help doctors to become more efficient at classifying types of cancer. They can then more precisely identify and group cancerous cells by similar characteristics. Reaching higher levels of accuracy of genomic identification leads to much better outcomes for sufferers.

One significant result of genomic sequencing; providing greater value in treatment options to those with rare cancers. To this point, these patients were left with little hope because they have had treatment options that at best were limited, and at worst ineffective. The new research at Rutgers is beginning to help even those patients whose cancers are no longer responsive.

Mr. Omar Boraie is hopeful that his family’s pledge will encourage others to do the same. He is no stranger to chemistry, has long been interested in cancer research, and remains dedicated to moving the cancer research forward by developing translational clinical treatments. The entire article is available here.